Perry Elliott

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Pathogenesis of cardiotoxicity induced by anthracyclines
    Perry Elliott
    The Heart Hospital, University College London Hospitals, London, UK
    Semin Oncol 33:S2-7. 2006
  2. doi request reprint Anderson-Fabry disease and the heart
    Constantinos O'Mahony
    Inherited Cardiac Diseases Unit, The Heart Hospital, University College London, UK
    Prog Cardiovasc Dis 52:326-35. 2010
  3. doi request reprint The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy
    Constantinos O'Mahony
    The Heart Hospital, 16 18 Westmoreland Street, London, UK
    Heart 98:116-25. 2012
  4. doi request reprint Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey
    Perry Elliott
    he Heart Hospital, University College London, London, UK
    Heart 97:1957-60. 2011
  5. ncbi request reprint Optimization of concomitant medication in Fabry cardiomyopathy
    Lydia Close
    The Heart Hospital, University College, London, UK
    Acta Paediatr Suppl 96:81-3. 2007

Collaborators

  • Derralynn A Hughes
  • Constantinos O'Mahony
  • Lydia Close
  • William McKenna
  • Shereen Al-Shaikh
  • Samer Arnous
  • Margherita Calcagnino
  • Sue Jones
  • Shafiqur M Rahman
  • Konstantinos Tsovolas
  • Giovanni Quarta
  • Pier D Lambiase
  • Montserrat Cardona

Detail Information

Publications5

  1. ncbi request reprint Pathogenesis of cardiotoxicity induced by anthracyclines
    Perry Elliott
    The Heart Hospital, University College London Hospitals, London, UK
    Semin Oncol 33:S2-7. 2006
    ....
  2. doi request reprint Anderson-Fabry disease and the heart
    Constantinos O'Mahony
    Inherited Cardiac Diseases Unit, The Heart Hospital, University College London, UK
    Prog Cardiovasc Dis 52:326-35. 2010
    ....
  3. doi request reprint The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy
    Constantinos O'Mahony
    The Heart Hospital, 16 18 Westmoreland Street, London, UK
    Heart 98:116-25. 2012
    ....
  4. doi request reprint Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey
    Perry Elliott
    he Heart Hospital, University College London, London, UK
    Heart 97:1957-60. 2011
    ..The aim of this study was to determine the prevalence of AFD in a large, consecutive cohort of patients with hypertrophic cardiomyopathy (HCM) using rapid mutation screening...
  5. ncbi request reprint Optimization of concomitant medication in Fabry cardiomyopathy
    Lydia Close
    The Heart Hospital, University College, London, UK
    Acta Paediatr Suppl 96:81-3. 2007
    ..CONCLUSION: In the era of enzyme replacement therapy, conventional pharmacological and device-based therapies remain central to the management of cardiovascular symptoms and the prevention of complications, such as arrhythmia and stroke...